SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Enfusion, Inc. (ENFN) trades at a trailing P/E of 803.0, forward P/E of 29.0. Trailing earnings yield is 0.12%, forward earnings yield 3.45%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (15/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 803.0); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY 0.12%).
- Forward P/E 29.0 (down from trailing 803.0) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 0.12% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 3.45% as earnings recover.
Overall SharesGrow Score: 54/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
15/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ENFN
Valuation Multiples
P/E (TTM)803.0
Forward P/E29.0
PEG Ratio0.01
Forward PEG0.01
P/B Ratio0.00
P/S Ratio6.91
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.01
Forward EPS (Est.)$0.37
Book Value / Share$0.00
Revenue / Share$1.56
FCF / Share$0.00
Yields & Fair Value
Earnings Yield0.12%
Forward Earnings Yield3.45%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$0.11 |
$59.03M |
$12.66M |
21.4% |
| 2020 |
$0.04 |
$79.57M |
$4.06M |
5.1% |
| 2021 |
$-4.30 |
$111.7M |
$-282.24M |
-252.7% |
| 2022 |
$-0.16 |
$150.35M |
$-13.26M |
-8.8% |
| 2023 |
$0.07 |
$174.54M |
$6.03M |
3.5% |
| 2024 |
$0.01 |
$201.61M |
$2.82M |
1.4% |
